4 completed, 1 unknown. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 4, Unknown 1 |
Follow FluBlok: new trials by email Literature Review of FluBlok trials Research Report on FluBlok
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity of Influenza Vaccinations Flucelvax® (ccIIV3), Flublok® (RIV3) - Influenza | Phase 4 | Completed | Duke University | 606 | 2024-09-09 | 2026-07-28 |
| Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures FluBlok, Placebo - Influenza, Human | Phase 4 | Completed | The University of Hong Kong | 977 | 2020-10-05 | 2026-05-15 |
| Recombinant Influenza Vaccination in U.S. Nursing Homes Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine - Influenza, Influenza -Like Illness | Phase 4 | Unknown | Insight Therapeutics, LLC | 1989 | 2019-07-20 | 2023-03-15 |
| Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP Flublok, Flucelvax, Fluarix - Influenza | Phase 4 | Completed | Centers for Disease Control and Prevention | 944 | 2018-09-12 | 2024-07-22 |
| Comparison of Three Licensed Influenza Vaccines FluBlok, Fluzone, FluCelVax - Influenza | Phase 4 | Completed | University of Rochester | 413 | 2015-10-28 | 2021-11-30 |
Influenza, Human (5)
Centers for Disease Control and Prevention (1) · Duke University (1) · Insight Therapeutics, LLC (1) · The University of Hong Kong (1) · University of Rochester (1)
United States (4) · Hong Kong (1)
Angela Branche, MD (1) · Brendan Flannery, PhD (1) · Emmanuel B Walter, MD, MPH (1) · Fatimah Dawood, MD (1) · H. Edward Davidson, PharmD, MPH (1) · Stefan Gravenstein, MD, MPH (1)
PMID 31598646, PMID 34245243, PMID 36031405, PMID 38177116, PMID 39041887, PMID 39745702, PMID 42856744
272201400005C-P00019-9999-4 (1), U01AI153700 (1)